Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Scandinavian Journal of Clinical and Laboratory Investigation|June 10, 2024
Managing hemolysis in serum neuron-specific enolase measurements - an automated algorithm for routine practiceRagnhild V Nome, Elisabeth Paus, Johanna E Gehin, et al.
Rheumatology International|May 4, 2021
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohortJohanna E Gehin, Rolf A Klaasen, Ellen S Norli, et al.
Rheumatology (Oxford, England)|September 29, 2023
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseasesIngrid Jyssum, Johanna E Gehin, Joseph Sexton, et al.
Therapeutic Drug Monitoring|February 2, 2026
The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III TrialJohanna E Gehin, Rolf A Klaasen, Eirik K Kristianslund, et al.
Scientific Reports|June 3, 2021
BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitorsBorja Hernández-Breijo, Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, et al.
Clinical and Experimental Rheumatology|January 10, 2024
Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritisAna Martínez-Feito, Chamaida Plasencia-Rodríguez, Marta Novella-Navarro, et al.
BMJ Neurology Open|March 25, 2026
Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumabEinar August Høgestøl, Åge Winje Brustad, Elisabeth Gulowsen Celius, et al.
Trials|January 8, 2020
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)Silje W Syversen, Guro L Goll, Kristin K Jørgensen, et al.
The Lancet. Rheumatology|February 25, 2024
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trialsMarthe Kirkesæther Brun, Johanna E Gehin, Kristin Hammersbøen Bjørlykke, et al.
Journal of Internal Medicine|February 27, 2023
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseasesMarthe Kirkesaether Brun, Kristin Hammersbøen Bjørlykke, Marte K Viken, et al.
Pageof 1